Loading...
Header Logo

Please contact mskhan2@childrensnational.org for any questions. Can't find your name in profiles ? Request a Profile

Keywords
Last Name
Institution

Rood, Brian

TitleAssociate Professor
InstitutionChildrens National Medical Center
DepartmentOncology
Address111 Michigan Ave NW
Washington DC 20010
Phone(202) 4762314
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Morrissy AS, Cavalli FMG, Remke M, Ramaswamy V, Shih DJH, Holgado BL, Farooq H, Donovan LK, Garzia L, Agnihotri S, Kiehna EN, Mercier E, Mayoh C, Papillon-Cavanagh S, Nikbakht H, Gayden T, Torchia J, Picard D, Merino DM, Vladoiu M, Luu B, Wu X, Daniels C, Horswell S, Thompson YY, Hovestadt V, Northcott PA, Jones DTW, Peacock J, Wang X, Mack SC, Reimand J, Albrecht S, Fontebasso AM, Thiessen N, Li Y, Schein JE, Lee D, Carlsen R, Mayo M, Tse K, Tam A, Dhalla N, Ally A, Chuah E, Cheng Y, Plettner P, Li HI, Corbett RD, Wong T, Long W, Loukides J, Buczkowicz P, Hawkins CE, Tabori U, Rood BR, Myseros JS, Packer RJ, Korshunov A, Lichter P, Kool M, Pfister SM, Schüller U, Dirks P, Huang A, Bouffet E, Rutka JT, Bader GD, Swanton C, Ma Y, Moore RA, Mungall AJ, Majewski J, Jones SJM, Das S, Malkin D, Jabado N, Marra MA, Taylor MD. Spatial heterogeneity in medulloblastoma. Nat Genet. 2017 May; 49(5):780-788. PMID: 28394352.
      View in: PubMed
    2. Paget S, Dubuissez M, Dehennaut V, Nassour J, Harmon BT, Spruyt N, Loison I, Abbadie C, Rood BR, Leprince D. HIC1 (hypermethylated in cancer 1) SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response (DDR) to irreparable DNA double-strand breaks (DSBs). Oncotarget. 2017 Jan 10; 8(2):2916-2935. PMID: 27935866.
      View in: PubMed
    3. Staal JA, Pei Y, Rood BR. A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors. Int J Mol Sci. 2016 Oct 19; 17(10). PMID: 27775567.
      View in: PubMed
    4. Waye S, Naeem A, Choudhry MU, Parasido E, Tricoli L, Sivakumar A, Mikhaiel JP, Yenugonda V, Rodriguez OC, Karam SD, Rood BR, Avantaggiati ML, Albanese C. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells. Aging (Albany NY). 2015 Oct; 7(10):854-68. PMID: 26540407; PMCID: PMC4637210.
      View in: PubMed, PubMed Central
    5. Staal JA, Lau LS, Zhang H, Ingram WJ, Hallahan AR, Northcott PA, Pfister SM, Wechsler-Reya RJ, Rusert JM, Taylor MD, Cho YJ, Packer RJ, Brown KJ, Rood BR. Proteomic profiling of high risk medulloblastoma reveals functional biology. Oncotarget. 2015 Jun 10; 6(16):14584-95. PMID: 25970789; PMCID: PMC4546489.
      View in: PubMed, PubMed Central
    6. Bhatia S, Baig NA, Timofeeva O, Pasquale EB, Hirsch K, MacDonald TJ, Dritschilo A, Lee YC, Henkemeyer M, Rood B, Jung M, Wang XJ, Kool M, Rodriguez O, Albanese C, Karam SD. Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget. 2015 Apr 20; 6(11):8929-46. PMID: 25879388; PMCID: PMC4496193.
      View in: PubMed, PubMed Central
    7. Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol. 2015 Jan; 121(1):217-24. PMID: 25407389; PMCID: PMC4330963.
      View in: PubMed, PubMed Central
    8. Karunasena E, McIver LJ, Rood BR, Wu X, Zhu H, Bavarva JH, Garner HR. Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas. Oncotarget. 2014 Aug 15; 5(15):6003-14. PMID: 25153720; PMCID: PMC4171608.
      View in: PubMed, PubMed Central
    9. Avery RA, Hwang EI, Ishikawa H, Acosta MT, Hutcheson KA, Santos D, Zand DJ, Kilburn LB, Rosenbaum KN, Rood BR, Schuman JS, Packer RJ. Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. JAMA Ophthalmol. 2014 Mar; 132(3):265-71. PMID: 24435762; PMCID: PMC4445404.
      View in: PubMed, PubMed Central
    10. Saratsis AM, Kambhampati M, Snyder K, Yadavilli S, Devaney JM, Harmon B, Hall J, Raabe EH, An P, Weingart M, Rood BR, Magge SN, MacDonald TJ, Packer RJ, Nazarian J. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol. 2014; 127(6):881-95. PMID: 24297113; PMCID: PMC4028366.
      View in: PubMed, PubMed Central
    11. Dubuissez M, Faiderbe P, Pinte S, Dehennaut V, Rood BR, Leprince D. The Reelin receptors ApoER2 and VLDLR are direct target genes of HIC1 (Hypermethylated In Cancer 1). Biochem Biophys Res Commun. 2013 Oct 25; 440(3):424-30. PMID: 24076391.
      View in: PubMed
    12. Rood BR, Leprince D. Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics. Expert Opin Ther Targets. 2013 Jul; 17(7):811-27. PMID: 23566242; PMCID: PMC3683369.
      View in: PubMed, PubMed Central
    13. Yeo KK, Puscasiu E, Keating RF, Rood BR. Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide. J Neurosurg Pediatr. 2013 Jun; 11(6):682-6. PMID: 23540527.
      View in: PubMed
    14. Albanese C, Rodriguez OC, VanMeter J, Fricke ST, Rood BR, Lee Y, Wang SS, Madhavan S, Gusev Y, Petricoin EF, Wang Y. Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challenges. Am J Pathol. 2013 Feb; 182(2):312-8. PMID: 23219428; PMCID: PMC3969503.
      View in: PubMed, PubMed Central
    15. Sirajuddin P, Das S, Ringer L, Rodriguez OC, Sivakumar A, Lee YC, Üren A, Fricke ST, Rood B, Ozcan A, Wang SS, Karam S, Yenugonda V, Salinas P, Petricoin E, Pishvaian M, Lisanti MP, Wang Y, Schlegel R, Moasser B, Albanese C. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle. 2012 Oct 15; 11(20):3801-9. PMID: 22983062.
      View in: PubMed
    16. Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013 May; 60(5):776-82. PMID: 22976922.
      View in: PubMed
    17. Brown KJ, Formolo CA, Seol H, Marathi RL, Duguez S, An E, Pillai D, Nazarian J, Rood BR, Hathout Y. Advances in the proteomic investigation of the cell secretome. Expert Rev Proteomics. 2012 Jun; 9(3):337-45. PMID: 22809211; PMCID: PMC3500636.
      View in: PubMed, PubMed Central
    18. Saratsis AM, Yadavilli S, Magge S, Rood BR, Perez J, Hill DA, Hwang E, Kilburn L, Packer RJ, Nazarian J. Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. Neuro Oncol. 2012 May; 14(5):547-60. PMID: 22492959; PMCID: PMC3337313.
      View in: PubMed, PubMed Central
    19. Yalon M, Rood B, MacDonald TJ, McCowage G, Kane R, Constantini S, Packer RJ. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer. 2013 Jan; 60(1):71-6. PMID: 22434731.
      View in: PubMed
    20. Boulay G, Malaquin N, Loison I, Foveau B, Van Rechem C, Rood BR, Pourtier A, Leprince D. Loss of Hypermethylated in Cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through ß-2 adrenergic receptor (ADRB2) misregulation. J Biol Chem. 2012 Feb 17; 287(8):5379-89. PMID: 22194601; PMCID: PMC3285317.
      View in: PubMed, PubMed Central
    21. Foveau B, Boulay G, Pinte S, Van Rechem C, Rood BR, Leprince D. The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). J Biol Chem. 2012 Feb 17; 287(8):5366-78. PMID: 22184117; PMCID: PMC3285316.
      View in: PubMed, PubMed Central
    22. Dubrovsky L, Wong EC, Perez-Albuerne E, Loechelt B, Kamani N, Sande J, Mintz K, Paul W, Luban NL, Rood BR, Fry T. CD34? collection efficiency as a function of blood volumes processed in pediatric autologous peripheral blood stem cell collection. J Clin Apher. 2011; 26(3):131-7. PMID: 21294153.
      View in: PubMed
    23. Chao MM, Packer RJ, Myseros JS, Rood BR. Isolated extracranial recurrence of anaplastic ependymoma. Pediatr Blood Cancer. 2011 Feb; 56(2):317-8. PMID: 20830772.
      View in: PubMed
    24. Rajagopal MU, Hathout Y, MacDonald TJ, Kieran MW, Gururangan S, Blaney SM, Phillips P, Packer R, Gordish-Dressman H, Rood BR. Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics. 2011 Mar; 11(5):935-43. PMID: 21271676; PMCID: PMC3088509.
      View in: PubMed, PubMed Central
    25. Rogers SK, Gomez CF, Carpenter P, Farley J, Holson D, Markowitz M, Rood B, Smith K, Nigra P. Quality of life for children with life-limiting and life-threatening illnesses: description and evaluation of a regional, collaborative model for pediatric palliative care. Am J Hosp Palliat Care. 2011 May; 28(3):161-70. PMID: 20826494.
      View in: PubMed
    26. Smith C, Santi M, Rajan B, Rushing EJ, Choi MR, Rood BR, Cornelison R, MacDonald TJ, Vukmanovic S. A novel role of HLA class I in the pathology of medulloblastoma. J Transl Med. 2009 Jul 12; 7:59. PMID: 19594892; PMCID: PMC2714836.
      View in: PubMed, PubMed Central
    27. Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009 Jul; 52(7):791-5. PMID: 19165892.
      View in: PubMed
    28. Van Rechem C, Rood BR, Touka M, Pinte S, Jenal M, Guérardel C, Ramsey K, Monté D, Bégue A, Tschan MP, Stephan DA, Leprince D. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem. 2009 Jul 31; 284(31):20927-35. PMID: 19525223; PMCID: PMC2742858.
      View in: PubMed, PubMed Central
    29. Crawford JR, Rood BR, Rossi CT, Vezina G. Medulloblastoma associated with novel PTCH mutation as primary manifestation of Gorlin syndrome. Neurology. 2009 May 05; 72(18):1618. PMID: 19414732.
      View in: PubMed
    30. Pistollato F, Chen HL, Rood BR, Zhang HZ, D'Avella D, Denaro L, Gardiman M, te Kronnie G, Schwartz PH, Favaro E, Indraccolo S, Basso G, Panchision DM. Hypoxia and HIF1alpha repress the differentiative effects of BMPs in high-grade glioma. Stem Cells. 2009 Jan; 27(1):7-17. PMID: 18832593.
      View in: PubMed
    31. Fleuriel C, Touka M, Boulay G, Guérardel C, Rood BR, Leprince D. HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol. 2009 Jan; 41(1):26-33. PMID: 18723112; PMCID: PMC2631403.
      View in: PubMed, PubMed Central
    32. Choi LM, Rood B, Kamani N, La Fond D, Packer RJ, Santi MR, Macdonald TJ. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer. 2008 May; 50(5):970-5. PMID: 17941070.
      View in: PubMed
    33. Thorarinsdottir HK, Rood B, Kamani N, Lafond D, Perez-Albuerne E, Loechelt B, Packer RJ, MacDonald TJ. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007 Mar; 48(3):278-84. PMID: 16456857.
      View in: PubMed
    34. Rood BR, MacDonald TJ. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol. 2005 Dec; 75(3):267-72. PMID: 16195804.
      View in: PubMed
    35. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol. 2004 Oct; 31(5):666-75. PMID: 15497120.
      View in: PubMed
    36. Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guérardel C, Leprince D. The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem. 2004 Sep 10; 279(37):38313-24. PMID: 15231840.
      View in: PubMed
    37. Rood BR, Zhang H, Cogen PH. Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro Oncol. 2004 Jul; 6(3):200-7. PMID: 15279712; PMCID: PMC1872000.
      View in: PubMed, PubMed Central
    38. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg. 2003 Jul; 39(2):60-7. PMID: 12845195.
      View in: PubMed
    39. Chopra A, Brown KM, Rood BR, Packer RJ, MacDonald TJ. The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma. Pediatr Neurosurg. 2003 Jul; 39(2):68-74. PMID: 12845196.
      View in: PubMed
    40. MacDonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cogen PH, Packer RJ. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist. 2003; 8(2):174-86. PMID: 12697942.
      View in: PubMed
    41. Rood BR, Zhang H, Weitman DM, Cogen PH. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res. 2002 Jul 01; 62(13):3794-7. PMID: 12097291.
      View in: PubMed
    Rood's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (306) concept(s)
    _
    Co-Authors Expand Description
    See all (19) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _